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MigrationFibrosis is a pathological situation inwhich excessive amounts of extracellular matrix (ECM) are deposited in the
tissue. Myoﬁbroblasts play a crucial role in the development and progress of ﬁbrosis as they actively synthesize
ECM components such as collagen I, ﬁbronectin and connective tissue growth factor (CTGF) and cause organ
ﬁbrosis. Transforming growth factor beta 1 (TGF-β1) plays a major role in tissue ﬁbrosis. Activin receptor-like
kinase 1 (ALK1) is a type I receptor of TGF-β1 with an important role in angiogenesis whose function in
cellular biology and TGF-β signaling is well known in endothelial cells, but its role in ﬁbroblast biology and its
contribution to ﬁbrosis is poorly studied. We have recently demonstrated that ALK1 regulates ECM protein
expression in amousemodel of obstructive nephropathy. Our aimwas to evaluate the role of ALK1 in several pro-
cesses involved in ﬁbrosis such as ECM protein expression, proliferation andmigration in ALK1+/+ and ALK1+/−
mouse embryonic ﬁbroblasts (MEFs) after TGF-β1 stimulations and inhibitors. ALK1 heterozygous MEFs show
increased expression of ECM proteins (collagen I, ﬁbronectin and CTGF/CCN2), cell proliferation and migration
due to an alteration of TGF-β/Smad signaling. ALK1 heterozygous disruption shows an increase of Smad2 and
Smad3 phosphorylation that explains the increases in CTGF/CCN2, ﬁbronectin and collagen I, proliferation and
cell motility observed in these cells. Therefore, we suggest that ALK1 plays an important role in the regulation
of ECM protein expression, proliferation and migration.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Tissue ﬁbrosis is an endpoint feature of several pathologies in
kidney, liver, lung, heart and skin [1]. Extracellular matrix (ECM)
protein synthesis, cellular proliferation, and migration are three impor-
tant processes in the development of tissue ﬁbrosis [2,3]. Transforming
growth factor-beta 1 (TGF-β1) plays a relevant role in tissue ﬁbrosis [4]
inducing ECM protein expression proliferation and migration in cells
such as stellate cells [5], ﬁbroblasts [6,7] and keratinocytes [8]. TGF-β1
signals by binding to a receptor complex formed by one type I receptor,
one type II receptor and, in some cases a type III co-receptor. Both type I
and type II receptors are necessary for TGF-β to exert its biological
functions [9]. Two type I receptors have been described for TGF-β1,
activin receptor-like kinase type 1 (ALK1) and type 5 (ALK5) [10,11].
TGF-β1 binding to an ALK1-containing receptor promotes Smad1/5
phosphorylation whereas TGF-β1 binding to an ALK5-containingnd Pharmacology, University of
Unamuno; 37007 Salamanca,
o).receptor promotes Smad2/3 phosphorylation, that is usually associated
with increased ECM protein expression [12].
Goumans et al. [13] have described that ALK1 and its effectors
(Smad1/5) exert a lateral antagonism of the ALK5 pathway. However,
ALK5 is necessary for the activation of the ALK1 pathway by TGF-β.
This mechanism has been described in endothelial cells [10,13–15].
Other authors have also demonstrated that ALK5 is necessary for TGF-
β-induced activation of the Smad1/5 pathway in L6E9 myoblasts [16].
Although the involvement of ALK1-Smad1/5 signaling pathway has
been described mainly for angiogenesis, there are some evidences that
it is also involved in ECM regulation [17]. Thus, it has been described
that the ratio ALK1/ALK5 regulates ECMprotein degradation in osteoar-
thritis, due to a regulation mechanism through MMP-13 [18]. In addi-
tion, Finnson et al. [19] showed that ALK1 negatively regulates TGF-
β1/ALK5-induced ECM protein expression in human chondrocytes.
Silencing of ALK1 with siRNA leads to an increase in TGF-β1-induced
connective tissue growth factor (CTGF/CCN2) expression [20]. Howev-
er, in other experimental models of tissue ﬁbrosis, it has been de-
monstrated that ALK1 behaves as a proﬁbrotic receptor: In liver
ﬁbrosis, ALK1 induces hepatic stellate cell transdifferentiation into
myoﬁbroblasts [21]. On the other hand, ALK1 promotes skin ﬁbrosis
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renal ﬁbrosis induced by radiation, mainly due to reduced inﬁltration
of inﬂammatory cells [23].
We recently demonstrated that ALK1 expression increases after
15 days of unilateral ureteral obstruction (UUO), an in vivo experimen-
talmodel of renal ﬁbrosis. This increase is observedmainly in interstitial
myoﬁbroblasts. Furthermore, ALK1 haploinsufﬁcient mice develop
more renal ﬁbrosiswhich is explained by the effect of ALK1 in regulating
ECMprotein expression in renal ﬁbroblasts [24]. These data suggest that
ALK1 is involved in the regulation of renal ﬁbrosis.
As ﬁbroblasts play a major role in tissue ﬁbrosis, our purpose is
to analyze the role of ALK1 in ECM protein expression, proliferation
and migration in ﬁbroblasts. It should be noted that ALK1 knock out
(KO) mice (ALK1−/−) die at E.11.5 due to cardiovascular defects
[25] and ﬁbroblasts derived from ALK1−/− embryos are not viable,
since they survive for only a few hours in culture conditions. Thus,
we have cultured ALK1 mouse embryonic ﬁbroblasts (MEFs) from
heterozygous (ALK1+/−) mice and their respective wild type con-
trols (ALK1+/+).
2. Materials and methods
2.1. Mice model of ALK1 haploinsufﬁciency
Generation of ALK1+/−micewas performed as previously described
[25]. ALK1+/−micewere given byDr. Peter tenDijke (LeidenUniversity,
Netherland), and a breeding colony of adult ALK1+/− mice has been
maintained in the pathogen-free facilities for genetically modiﬁed
mice of the University of Salamanca, and backcrossed with C57Bl/6
mice for 9 generations. Routine genotyping of DNA isolated from
mouse tail biopsies was performed by PCR using the primers previously
reported [25]. Animals were kept under controlled ambient conditions
(Animal Experimentation Service, University of Salamanca, Spain) in a
temperature controlled-room with a 12 h light/dark cycle, and were
reared on standard chow (Panlab, Barcelona, Spain) and water ad
libitum. In all procedures, mice were treated in accordance with the
Recommendations of the Helsinki Declaration on the Advice on Care
and Use of Animals referred to in: law 14/2 007 (3 July) on Biomedical
Research, Conseil de l'Europe (published in Ofﬁcial Daily N. L358/
1-358/6, 18-12-1986), Spanish Government (Royal Decree 223/1 988,
(14 March) and Order of October 13 1989, and Ofﬁcial Bulletin of the
State b. 256, pp. 31349–31362, October 10 1990). All the procedures
were approved by the Bioethics committee of the University of
Salamanca.
2.2. ALK1+/− ﬁbroblast generation, cell culture and TGF-β1 stimulation
ALK1+/+ and ALK1+/−MEFs were subcultured and immortalized as
previously reported [26]. Brieﬂy, mouse embryos obtained from the
mating of ALK1+/− mice were recovered at DPC 10, mechanically
minced and treated with 0.25% trypsin solution for 30 min before plat-
ing on DMEM supplemented with 10% FCS, 0.66 μg/ml penicillin and
60 μg/ml streptomycin sulfate, in an atmosphere of 95% air/5% CO2 at
37 °C. Immortalized cultures that survived crises after 15–20 passages
were identiﬁed and cloned and their genotypes reconﬁrmed by PCR
analysis as described previously [25]. ForWestern blot and PCR analysis,
cells were seeded in 100mm culture dishes, for total collagenmeasure-
ments and proliferation studies cells were plated respectively at 20,000
or 9000 cells/well in 24 well plates. When cultures achieved 80–90%
conﬂuence, cells were serum-starved for 24 h and treated with active
human recombinant TGF-β1 (1 ng/mL) or control vehicle during 30
min or 24 h in the absence of serum. When pharmacological inhibition
was used, the ALK5 inhibitor SB431542 [27] (5 μM) or the Smad3 inhib-
itor SIS3 (4 μM) [28]were added 30min before TGF-β1 stimulation. Cul-
tures of similar percentage of conﬂuence were used in every analysis
performed.2.3. Western blot
Total cell extracts were homogenized in magnesium lysis buffer
(MLB, from Millipore, Billerica, MA, USA) supplemented with 80% glyc-
erol, 1 mg/mL leupeptin, 1 mg/mL aprotinin, 10 mM PMSF, 1 mmol/L
Na3VO4 and 25 mmol/L NaF, and centrifuged at 14,000 g during
20 min. Supernatants were recovered and the protein amount was
quantiﬁed. Lysates (20 μg per lane) were loaded onto polyacrylamide
gels and the proteins were transferred to nitrocellulose membranes
(Millipore) by electroblotting. Next,membraneswere blocked in bovine
serum albumin (BSA) and were incubated overnight at 4 °C with the
following antibodies: rabbit anti-collagen type I (dilution 1:1000)
and rabbit anti-ﬁbronectin (1:1000) from Chemicon International
(Temecula, CA); rabbit anti-phospho-Smad3 (1:1000) and rabbit anti-
phospho-Smad1/5/8 (1:1000) from Cell Signaling (Barcelona, Spain);
goat anti-CTGF (1:1000), goat anti-Smad2/3 (1:1000), rabbit anti-
ALK5 (TβRI) (1:1000), and mouse anti-Smad1 (1:1000) from Santa
Cruz Biotechnology (Madrid, Spain), rabbit anti-ACVRL1 (ALK1)
(1:1000) from Abgent (Derio, Spain), rabbit anti-phospho-Smad1
(1:1000) and rabbit anti-phospho-Smad2 (1:1000) from Upstate Bio-
technology (Barcelona, Spain), and mouse anti-PCNA (1:1000) from
Transduction Laboratories (Madrid, Spain). Membranes were incubated
with the corresponding horseradish peroxidase-conjugated secondary
antibodies (1:10,000) and were developed using ECL chemilumines-
cence reagent (Amersham Biosciences, Barcelona, Spain). Developed
signals were recorded on X-ray ﬁlms (Fujiﬁlm Spain, Barcelona, Spain)
for densitometric analysis (Scion Image software, Frederick, MD, USA).
Erk1/2 was used as loading control.2.4. RT-PCR analysis
Total RNA was isolated as described previously [2]. Quantitative RT-
PCR was performed in triplicate. Each 20 μl reaction contained 1 μl of
cDNA, 400 nM of each primer, and 1× IQ SybrGreen Supermix (Bio-
Rad). Primers were designed for speciﬁc sequences and checked by
the BLAST algorithm as previously described [29]. Primers used were:
For mouse ALK1 (92 bp): forward 5′-CTGCTTTGAGTCGTACAAGT-3′
and reverse 5′-CCACAATGCCATTGATGATG-3. For mouse ALK5
(114 bp): forward 5′-CAGACAACAAAGACAATGGG-3′ and reverse 5′-
ATCATTCCTTCCACAGTAACAG-3′. For mouse GAPDH (153 bp): forward
5′-GTCGGTGTGAACGGATTTG–3′ and reverse 5′-GAATTTGCCGTGAGTG
GAGT-3′. Cycling conditions for ALK1, ALK5 and GAPDH: 95 °C, 5 min,
35 cycles of 1min 95 °C, 1min 59 °C and 1min 72 °C, and an elongation
cycle of 5 min 72 °C. Standard curves were run for each transcript to
ensure exponential ampliﬁcation and to rule out non-speciﬁc ampliﬁca-
tion. Gene expression was normalized to GAPDH expression. The reac-
tions were run on an iQ5 real-time PCR detection system (Bio-Rad).2.5. Wound-healing assay
In vitro scratchedwounds were created on serum-starved conﬂuent
cell monolayers with a straight incision using a sterile disposable pi-
pette tip. Cell migration into the denuded area was monitored over a
time course using digital microscopy and cell movementwas calculated
as the reduction of thewound area over time (in percentage, initial area
of the wound: 100%).2.6. Cell proliferation assay
Cells in 24 well plates were serum-starved when cultures achieved
80–90% conﬂuence during 48 h and 72 h and viable cell number was
measured using a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide) assay as previously described [30].
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Fibroblasts in cover slips were ﬁxed with 4% paraformaldehyde
(Sigma-Aldrich, Barcelona, Spain) washed with phosphate buffered sa-
line (PBS), permeabilized with 0.1% Triton X-100, blocked 30 min with
2% BSA in PBS, treated with PBS-0,05% Tween 20 for 10 min, and incu-
bated during 2 h with anti-α-SMA (Sigma-Aldrich), anti-Smad2/3,
anti-Smad1, anti-ALK1 and anti-ALK5 (Santa Cruz), Ki67 (Master
Diagnostica, Granada, Spain) or Oregon Green (Invitrogen) for total
actin detection. Later, cells were incubated 30 min with goat anti-
mouse or anti-rabbit Cy3 (Jackson Immunoresearch, West Grove PA,
USA) or Alexa anti-goat (Molecular Probes, Barcelona, Spain) (dilution
1:1000) in PBS in a dark chamber. Nuclei staining was performed by
5 min incubation with 2 μM Hoechst 33258 (Molecular Probes) in a
dark chamber. Cover slips were mounted on slides using Prolong gold
antifade (Molecular Probes). Confocal images were obtained as previ-
ously described [2].2.8. Statistical methods
Data are expressed as mean ± standard error of the mean (SEM).
The Kolmogorov–Smirnov test was used to assess the normality of the
data distribution. Comparison of means was performed by two way
analysis of variance (ANOVA) and Bonferroni post-test. Statistical differ-
ences between groups were assessed by the Student “t” test. Statistical
analysis was performed using GraphPad Prism version 5.00 for Win-
dows (GraphPad Software, San Diego, California, USA, www.graphpad.
com). A “p” value lower than 0.05 was considered statistically
signiﬁcant.3. Results
3.1. ALK1 is expressed in mouse embryonic ﬁbroblasts (MEFs)
MEFs genotyping was performed by PCR. A 300 bp band identiﬁed
ALK1+/+ MEFs, whereas a double band (300 bp and 360 bp) identiﬁed
ALK1+/−MEFs (Fig. 1a). Our data show that both ALK1 and ALK5 recep-
tors are expressed in MEFs. ALK1+/−MEFs show reduced ALK1 expres-
sion as well as normal levels of ALK5, as detected by Western-blot and
real-time PCR. Treatment with TGF-β1 does not induce changes in
ALK1 expression in both ALK1+/+ and ALK1+/− ﬁbroblasts but de-
creases ALK5 expression in ALK1+/− ﬁbroblasts and increases endoglin
expression in these cells (Fig. 1b, c). On the other hand, ALK1+/+
and ALK1+/− ﬁbroblasts show different cytoskeleton organization:
ALK1+/+ ﬁbroblasts show more focal adhesions whereas ALK1+/−
MEFs show more stress ﬁbers (Fig. 1d panels 1–2). ALK1+/+ and
ALK1+/−MEFs express themyoﬁbroblast marker alpha smooth muscle
actin (α-SMA) [31] (Fig. 1d panels 3–4). ALK1 and ALK5 protein were
detected also by immunoﬂuorescence in both ALK1+/+ and ALK1+/−
(Fig. 1d panels 5–8).3.2. ALK1+/−MEFs show higher expression of ECM proteins than ALK1+/+
MEFs
We assessed the basal and TGF-β1-induced expression of collagen
type I, ﬁbronectin and CTGF/CCN2 by Western blot. Collagen I (Fig. 2a),
ﬁbronectin (Fig. 2b) and CTGF/CCN2 (Fig. 2c) protein expressions are
signiﬁcantly higher in ALK1+/− than in control ALK1+/+ ﬁbroblasts in
basal conditions (Fig. 2a, b, c). TGF-β1 treatment induces an increase in
ﬁbronectin and CTGF/CCN2 expressions in both ALK1+/+ and ALK1+/−
ﬁbroblasts, this increase being higher in ALK1+/− than in ALK1+/+ ﬁbro-
blasts. TGF-β stimulates collagen I expression in control but not in
ALK1+/− ﬁbroblasts (Fig. 2).3.3. Increased cellular proliferation and migration in ALK1+/− ﬁbroblasts
Weassessed the role of ALK1 inﬁbroblast proliferation bymeasuring
the number of viable cells with the MTT assay during 48 h, and by
analyzing PCNA expression byWestern-blot andKi67 expression by im-
munoﬂuorescence. In basal conditions, ﬁbroblasts proliferation, PCNA
and Ki67 protein expression were higher in ALK1+/− than in WT ﬁbro-
blasts (Fig. 3a, c and d). TGF-β1 does not increase the number of viable
cells in ALK1+/+ ﬁbroblasts (Fig. 3b) although it induces a signiﬁcant
increase in PCNA expression in ALK1+/+ ﬁbroblasts (Fig. 3c). Moreover,
TGF-β1 does not induce any effect on Ki67 expression in ALK1+/+ ﬁbro-
blasts (Fig. 3d). By contrast, in ALK1+/− ﬁbroblasts TGF-β1 has no effect
on the number of cells (Fig. 3b) or PCNA (Fig. 3c) protein expression.
Moreover, TGF-β1 induces a decrease in Ki67 positive ALK1+/− ﬁbro-
blasts (Fig. 3d).
The role of ALK1 in ﬁbroblast migration was analyzed by an in vitro
wound-healing time-course assay during 20 h. We observed that the
healing time of the scratched area is lower in ALK1+/− than in ALK1+/+
ﬁbroblasts (Fig. 3e).
3.4. ALK1 heterozygous disruption modiﬁes TGF-β1/Smad signaling
In order to elucidate the intracellular signaling involved in the above
described processes, we studied TGF-β-related Smad phosphorylation
in basal conditions and after TGF-β1 treatment during 30 min. In basal
conditions Smad2 and Smad3 phosphorylation are higher in ALK1+/−
than in ALK1+/+ ﬁbroblasts. TGF-β1 treatment induces the phosphory-
lation of Smad2 and Smad3 in ALK1+/− and in WT ﬁbroblasts, this in-
duction being slightly higher in ALK1+/− than in WT ﬁbroblasts
(Fig. 4a). In basal conditions, phospho-Smad1 expression is signiﬁcantly
lower in ALK1+/− than in control ﬁbroblasts (Fig. 5a). Moreover, TGF-
β1 treatment increases Smad1 phosphorylation in ALK1+/− ﬁbroblasts
but not in control ﬁbroblasts (Fig. 5a). There are no signiﬁcant differ-
ences in total Smad2/3 and Smad1 expression between ALK1+/− and
ALK1+/+mouse embryonic ﬁbroblasts (Figs. 4a and 5a). On the other
hand, TGF-β1 treatment induces a translocation of the Smad2/3 protein
into the nucleus similar in both ALK1+/− and ALK1+/+ ﬁbroblasts
(Fig. 4b). TGF-β1 treatment does not induce translocation of Smad1
into the nucleus either in ALK1+/− or in ALK1+/+ ﬁbroblasts (Fig. 5b).
Although we detected a slight increase in Smad1 phosphorylation in
ALK1+/− ﬁbroblasts (Fig. 5a), that increase is not enough to detect
Smad1 nuclear translocation in these experimental conditions
(Fig. 5b). In summary, ALK1 heterozygosity modiﬁes TGF-β1/Smad sig-
naling decreasing ALK1/Smad1 phosphorylation.
3.5. Increased expression of ECM proteins in ALK1+/− ﬁbroblasts is
Smad2/3 dependent
As we observed that ALK1 heterozygous ﬁbroblasts express more
collagen I, ﬁbronectin and CTGF/CCN2, and showed increased Smad2
and Smad3 phosphorylation compared with WT ﬁbroblasts, we
assessed if this increase in ECM protein expression observed in ALK1
heterozygosity might be related to increased TGF-β1/ALK5 signaling,
by analyzing the effect of the ALK5 inhibitor SB431542 and the
phospho-Smad3 inhibitor SIS3 during 24 h on collagen I, ﬁbronectin
and CTGF/CCN2 expression.
SB431542 is a potent ALK5 inhibitor [27], and inhibits pSmad2,
pSmad3 and pSmad1/5 in L6E9 myoblasts [16] as well as phospho-
Smad2 and phospho-Smad3 in hepatocytes [32]. SIS3 has inhibitor ef-
fects on pSmad3 – but not pSmad2 – expression and on the subsequent
induction of ECM protein synthesis in ﬁbroblasts [28]. SIS3 inhibits
Smad3 phosphorylation but not Smad2 and Smad1 phosphorylation in
hepatocytes [32]. In summary, SB431542 inhibits pSmad2, pSmad3
and pSmad1/5, while SIS3 inhibits only pSmad3. As expected,
SB431542 treatment decreases TGF-β1-induced Smad2 and Smad3
phosphorylation as well as Smad1/5/8 phosphorylation (Fig. 6a).
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induced collagen I, ﬁbronectin, and CTGF/CCN2 expressions in
ALK1+/+ ﬁbroblasts (Fig. 6b1, 2, 3). No signiﬁcant changes in colla-
gen I expression in ALK1+/−ﬁbroblasts were observed after
SB431542 treatment (Fig. 6b1). Moreover, SB341542-induced
decreases in ﬁbronectin and CTGF/CCN2 expressions in ALK1+/−
ﬁbroblasts are larger than the decreases induced in ALK1+/+ ﬁbro-
blasts (Fig. 6b2, 3).
Treatment with SIS3 decreases TGF-β1-induced Smad3 but not
Smad2 phosphorylation. SIS3 also reduced the TGF-β-induced activa-
tion of the ALK1/Smad1/5/8 pathway. This is the ﬁrst description of
the inhibitory effect of SIS3 on Smad1/5/8 phosphorylation (Fig. 7a).Inhibition with SIS3 reduces slightly collagen I, ﬁbronectin and CTGF/
CCN2 expressions in ALK1+/+ ﬁbroblasts either in resting condition or
after stimulation with TGF-β1. SIS3-induced decreases in collagen I
and ﬁbronectin expressionswere larger in ALK1+/− than in ALK1+/+ ﬁ-
broblasts (Fig. 7b1, 2), but SIS3 reduces CTGF/CCN2 expression only in
WT ﬁbroblasts (Fig. 7b3).
3.6. Increased proliferation in ALK1+/− ﬁbroblasts is ALK5 dependent
The ALK5 inhibitor SB431542 (24 h) decreases ALK1+/+ and
ALK1+/− ﬁbroblast proliferation in basal conditions. Moreover, pre-
treatment with SB431542 (30 min) before TGF-β1 treatment for 24 h
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(Fig. 8a1). However, ALK5 inhibition increases basal and TGFβ-1-
induced PCNA expression in WT ﬁbroblasts but no differences were
observed in PCNA expression in ALK1+/− ﬁbroblasts (Fig. 8a2).The Smad3 inhibitor SIS3 decreases the number of viable cells
in ALK1+/+ and ALK1+/− ﬁbroblasts after 24 h in basal conditions
(Fig. 8b1). Moreover, pre-treatment with SIS3 (30 min) before TGF-β1
treatment for 24 h also decreases TGF-β1-induced proliferation in
both types ofﬁbroblasts (Fig. 8b1). SIS3 inhibition inhibits PCNA expres-
sion in ALK1+/− but not in ALK1+/+ ﬁbroblasts (Fig. 8b2).
3.7. Higher cell motility in ALK1+/− ﬁbroblasts is Smad3 dependent
We studied the possible role of ALK5/Smad2/3 pathways in ﬁbro-
blast migration in ALK1 haploinsufﬁcient ﬁbroblasts. ALK5 inhibition
with SB431542 slightly increases the time of wound-closure in
ALK1+/− and ALK1+/+ ﬁbroblasts (Fig. 9a, b). Treatment with the
Smad3 inhibitor SIS3 increases wound-closure time in both WT and
ALK1+/− ﬁbroblasts, this retardation being higher in ALK1+/− ﬁbro-
blasts, where the velocity of migration is reverted to levels similar to
those of the ALK1+/+ phenotype (Fig. 9a,b).
4. Discussion
In this study we show that ALK1 heterozygosity leads to an increase
in ECM protein expression (collagen I, ﬁbronectin and CTGF/CCN2), and
to an increase in proliferation and migration due to higher TGF-β1/
ALK5/Smad2/3 pathway activity. The higher expression of collagen I ob-
served in ALK1+/− ﬁbroblasts seems to be Smad3-dependent and the
higher expression of CTGF/CCN2 seems to be Smad2-dependent. On
the other hand, both Smad2 and Smad3 seem to be involved in the in-
creased levels of ﬁbronectin observed in ALK1 heterozygous ﬁbroblasts.
While increased proliferation in ALK1+/− ﬁbroblasts may be Smad2-
and Smad3- dependent, only Smad3 seems to lead to the higher cell
motility observed in ALK1 heterozygous ﬁbroblasts.
ALK1 was shown to be upregulated in obstructed kidneys. The
expression of ALK1 in ﬁbrotic kidneys is mainly due to myoﬁbroblasts
located in the tubular interstitium. Moreover, renal ﬁbroblasts in the
primary culture express both ALK1 and ALK5 receptors [24]. In the
present study we demonstrate for the ﬁrst time that ALK1 is expressed
in MEFs. As expected, ALK1 expression is lower in ALK1+/− than in
ALK1+/+ MEFs.
We recently described that ALK1+/− mice develop more
tubulointerstitial ﬁbrosis than WT mice after UUO [24] and the present
study is focused on the role of ﬁbroblasts as they are the main actors of
increased renal ﬁbrosis observed in ALK1 heterozygous mice. In agree-
ment with our previous studies [24], we demonstrate here that
ALK1+/−MEFs express more ECM proteins than WT MEFs. Moreover,
TGF-β1 induces in these cells a higher increase in CTGF/CCN2 and ﬁbro-
nectin expression than in ALK1+/+ ﬁbroblasts. Thus, our data suggest
that activation of the ALK1/Smad1 pathway has antiﬁbrotic effects.
These data are in agreement with other studies performed in different
cell types such as human chondrocytes [19,33], hepatocytes [20] and
myoblasts [16,34] showing a regulation of ECM protein expression
due to the ALK1/ALK5 signaling pathway ratio. This ratiowas previously
described in cartilage having an important role in the regulation of the
amount of MMP-13 [18]. Some recent articles on studies about the pos-
sible role of ALK1 in ﬁbrosis in other systems showed that ALK1 behaves
as a proﬁbrotic receptor, as it has been described in scleroderma ﬁbro-
blasts [22,35,6] and in hepatic ﬁbrosis [21]. However, the role of ALK1
in hepatic ﬁbrosis does not seem to be due to ﬁbroblast function but
to the dedifferentiation of hepatic stellate cells into myoﬁbroblasts
[21]. In hepatocytes, ALK1 overexpression leads to a decrease of TGF-
β-induced CTGF/CCN2 expression, with ALK1 acting as an antiﬁbrotic
receptor [20].
In this study, ALK1+/− ﬁbroblasts show reduced Smad1 phosphory-
lation in basal conditions as well as increased Smad2 and Smad3 phos-
phorylation in basal conditions and after TGF-β1 treatment, than
ALK1+/+ ﬁbroblasts. These data are in concordance with the traditional
model of TGF-β1 signaling, where ALK5 phosphorylates Smad2/3 and
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munoﬂuorescence; magniﬁcation: 200×, scale bar = 20 μm; d2) quantiﬁcation of Ki67 positive cells in ALK1+/+ and ALK1+/− MEFs; e) analysis of wound closure area in
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values (ALK1+/+). Histogram in (b) represents the mean of 33 experiments expressed as percentage over basal values (ALK1+/+ and ALK1+/− ﬁbroblasts in 0.5% FCS, 100%).
Histogram in (c) shows a representative blot of 11–15 experiments, performed under similar conditions and represents the mean ± SEM of the optical density of the bands.
Histogram in (d) represents the quantiﬁcation of the number of Ki67 positive cells vs. total cells. Curve graphs in (e) represent the mean ± SEM of 6 experiments evaluating
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tion is due to reduced expression of ALK1, while higher Smad2/3 phos-
phorylationmay be also due to reduced expression of ALK1 as Goumans
et al. [13,14] demonstrated that ALK1 (and its effectors Smad1/5) exert
a lateral antagonist of ALK5/Smad2/3 signaling in endothelial cells.
Thus, lower ALK1 expression may decrease this antagonism and thus
enhance Smad2/3 signaling.
ALK5/Smad2/3 pathway activation has been traditionally related to
TGF-β1-induced ECM protein expression [4,27,28]. The promoter
areas of COL1A2, COL3A1, COL5A1, COL6A1, COL6A3 and COL2A1 have
Smad3 binding sequences [4]. CTGF/CCN2 has Smad2 response ele-
ments. It has been also proposed that the CTGF/CCN2promoter contains
Smad3 response elements [37]. On the other hand, other authors have
demonstrated that Smad1 phosphorylation activates the CTGF/CCN2
promoter but in an Smad binding site-independent manner [22]. With
respect to ﬁbronectin, Hocevar et al. [38] showed that the TGF-β-
induced expression of ﬁbronectin was due to the activation of Jun N-
terminal kinase (JNK) by a Smad4-independent mechanism. However,
Laping et al. [27] later showed that ALK5 inhibition with SB431542
lead to a reduction in ﬁbronectin levels, due to a p38 dependent mech-
anism and the subsequent activation of ATF-2, CREB and AP-1. Isono
et al. [39] demonstrated that TGF-β-induced Smad3 phosphorylationstimulated the ﬁbronectin promoter in mesangial cells. Nevertheless,
to date there are no records of Smad response elements in the ﬁbronec-
tin promoter.
Nevertheless, while the role of Smad3 in ECM protein expression
and ﬁbrosis is clear [40,4], the role of Smad2 is controversial. Meng
et al. [41] have demonstrated that Smad2 protects against TGF-β1/
Smad3-induced renal ﬁbrosis. These authors demonstrated that
Smad2 KO MEFs express more ECM proteins due to a higher Smad3
phosphorylation as a protective mechanism. Our results show that the
higher levels of collagen I observed in ALK1+/− ﬁbroblasts are Smad3
dependent, but the increased levels of CTGF/CCN2 observed in ALK1
heterozygousﬁbroblasts are Smad2 dependent. These data are in agree-
mentwith those of several authors that have demonstrated a strong re-
lationship between Smad2 and CTGF/CCN2. For instance, Gressner et al.
[32] demonstrated in hepatocytes that inhibition with SB431542 but
not with SIS3 reduces TGF-β-induced CTGF/CCN2 expression, showing
that Smad2 – but not Smad3 – is responsible for TGF-β induction of
CTGF/CCN2.
As we described throughout the article, ALK1+/−MEFs show poten-
tiated ALK5 effects in basal conditions.We detected lower expression of
ALK5 in ALK1+/− ﬁbroblasts stimulated with TGF-β1, which seems to
suggest that it is possible that ALK1 heterozygous MEFs develop an
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lationwith TGF-β in order to palliate the higher ﬁbrotic effects observed
in these conditions.
It has been reported that ALK1 plays a pivotal role in endothelial cell
proliferation [36,11]. Fibroblast proliferation is an important feature in
ﬁbrotic and wound healing processes [42,3,24]. Truong et al. [43] de-
tected in ﬁbrotic kidneys the expression of proliferation markers in
two cellular populations: tubular cells and interstitial myoﬁbroblasts.
Our cell proliferation assays show that ALK1+/−MEFs show lower pro-
liferation than WT cells, thus suggesting that ALK1 acts as anantiproliferative receptor, probably due to its lateral inhibition of
ALK5/Smad2/3 pathways which may promote proliferation in our
MEFs. Our results indicate that the higher cell motility observed in
ALK1 heterozygous ﬁbroblasts is mainly due to the higher Smad3 phos-
phorylation observed in basal conditions. The role of ALK5/Smad2/
Smad3 in cell proliferation is controversial. Several authors have dem-
onstrated that TGF-β1 induces cell proliferation in culture [44,2,7].
However, despite the role of TGF-β1 in cell proliferation being cell
type-dependent, many authors have believed that TGF-β has a potential
role as a growth inhibitor factor [45]. Thus, Smad2 and Smad3 KO
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On the other hand, in the human glioma cell line U87MG, the TGF-β/
ALK5 inhibitor SB431542 inhibits cell proliferation [46]. In rat aortic
vascular smooth muscle cells, c-Ski inhibits proliferation due to an
inhibition of Smad3 phosphorylation, suggesting that Smad3 is in-
volved in cell proliferation [47]; this is in agreement with our exper-
iments, in which a reduced cell proliferation in both ALK1+/+ and
ALK1+/− ﬁbroblasts is observed after SIS3 treatment. Smad3 regu-
lates the role of TGF-β in ﬁbroblasts, but this role is different depend-
ing on the context or the characteristics of the population of
ﬁbroblasts studied: Smad3 inhibits proliferation in cardiac ﬁbro-
blasts after myocardial infarction [48], inhibits proliferation in oral
mucosa ﬁbroblasts but promotes proliferation in dermal ﬁbroblasts
[49,50]. In our study we have demonstrated that both ALK5 andSmad3 inhibition reduces ﬁbroblast proliferation and that increased
proliferation observed in ALK1+/− ﬁbroblasts is ALK5/Smad3 depen-
dent. Moreover, we have previously described that obstructed kid-
neys in ALK1+/− mice show a higher PCNA and Ki67 expression
than in control mice [24].
Cellular migration is an important process that leads myoﬁbroblasts
to repair the damaged tissue in wound healing and in ﬁbrosis develop-
ment. The function of ALK1 in cellular migration has been extensively
studied, mainly in angiogenic processes. ALK1/Smad1/5 pathways and
its target Id1 (inductor of diferentiation-1) were early related to endo-
thelial cell migration [36,11,51,52]. Nevertheless, other authors have
shown that ALK1 activation inhibits microvascular endothelial cell mi-
gration, due to the activation of MAP kinase pathways [53]. However,
Kocic et al. [8] have demonstrated that Smad3 is essential to cellular
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Smad3 with SIS3 decreased cellular migration and the expression of
urokinase type plasminogen activator [8]. Dobaczewski et al. [48] have
demonstrated that Smad3 KO ﬁbroblasts show reduced migration fol-
lowing myocardial infarction. Our results show that the higher levels
of Smad3 phosphorylation observed in ALK1+/−MEFs are responsible
for the increased migration observed in these cells. Moreover, these
data further conﬁrm that the role of TGF-β1 signaling is cell-type depen-
dent. On the other hand, our data show for the ﬁrst time the involve-
ment of the ALK1 receptor in cellular migration in a non-endothelial
cell.
In conclusion, our results show for the ﬁrst time the expression of
ALK1 in MEFs and the important role of this receptor in themodulation
of different processes involved in ﬁbrosis, such as ECM protein expres-
sion, proliferation and migration in ﬁbroblasts. ALK1 seems to have an
antiﬁbrotic role in our experimental model. Moreover, our data conﬁrmthat the role of ALK1 in the above mentioned processes is cell-type
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Fig. 9. Effect of SB431542 and SIS3 inhibition in ALK1+/+ and ALK1+/−MEFsmigration. a) Effect of ALK5 inhibitionwith 5 μMSB431542 and phospho-Smad3 inhibitionwith 4 μMSIS3 on
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